Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Texas Medical Center
1102 Bates Ave., Ste. 1220
Houston, TX 77030
Pavel Sumazin, PhD
Director, Bioinformatics Core Laboratory, Cancer and Hematology Center
Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
|Cold Spring Harbor Laboratory||Post-doctoral Fellow||Human genetics|
|Columbia University||Fellowship||Systems Biology|
|Stony Brook University||University||Doctor of Philosophy, Computer Science|
Dr. Pavel Sumazin is Director of the Bioinformatics Core Laboratory and a member of the Cancer Genetics and Genomics Program and the Center for Precision Oncology at Texas Children's Cancer and Hematology Center, and the Quantitative and Computational Biosciences Department, Therapeutic Innovation Center, and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine.
Dr. Sumazin studies cancer systems biology, including technology development and its applications to cancer genomics. He’s contributed to comparative studies of cancers, studies of non-coding RNAs in cancer, and the design of diagnostic algorithms to optimize therapies for cancer patients. He helped design biochemical and computational technologies to resolve the composition and phylogeny of cancers, and he helped identify cancer clones that influence etiology, progression, and response to therapies.
Dr. Pavel Sumazin interprets molecular profiles of human tumors to inform cancer diagnostics and therapeutics. He aims to infer pathophysiological consequences of somatic and germline alterations by mapping out amplification and propagation pathways that channel their effects to alter the activity of cancer genes. Towards this goal, he has helped reverse-engineer transcriptional and post-transcriptional regulatory networks in multiple human cancers, identifying genes that regulate cell survival and proliferation, DNA damage response, and cancer progression. Specifically, Dr. Sumazin has helped identify a molecular signature to distinguish indolent from aggressive prostate cancer (Irshad, 2013), a tumor suppressor tRNA-derived microRNA in B cell lymphoma (Basso, 2009; Maute, 2013), genes that target tumor-suppressors PTEN and RB1 through competition for microRNA regulation in glioblastoma (Sumazin, 2011), and transcription factors that regulate proliferation in germinal centers (Lefebvre, 2010; Basso, 2010).
Shazia Irshad, Mukesh Bansal, Mireia Castillo-Martin, Tian Zheng, Alvaro Aytes, Sven Wenske, Clémentine Le Magnen, Paolo Guarnieri, Pavel Sumazin, Mitchell C. Benson, Michael M. Shen, Andrea Califano, Cory Abate-Shen. A Molecular Signature Predictive of Indolent Prostate Cancer. Science Translational medicine, 202(5):1-12, 2013.
Pavel Sumazin, Xuerui Yang, Hua-Sheng Chiu, Wei-Jen Chung, Archana Iyer, David Llobet-Navas, Presha Rajbhandari, Mukesh Bansal, Paolo Guarnieri, Jose Silva, Andrea Califano: An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell, 147(2):370-81, 2011.
Katia Basso, Pavel Sumazin, Pavel Morozov, Christof Schneider, Yukiko Kitagawa, Roy L. Maute, Jonathan Mandelbaum, Joseph Haddad, Chang-Zheng Chen, Andrea Califano and Riccardo Dalla-Favera: Identification of the human mature B cells miRNome. Immunity, 30(5):744-752, 2009.
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.